Given the encouraging results achieved by human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer patients with HER2-low [1], it is important to fully understand the biological and clinical features of this subgroup [2, 3], as well as noninvasively stratify patients prior to treatment. This evidence concerns the gene ERBB2 and breast cancer.